Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Adverse Events | NCT00728949 | There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00728949', 'Intervention': ['INTERVENTION 1: ', ' IMC-A12 (Cixutumumab) + Antiestrogen Therapy', ' Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cb9f8a52-b88e-4b04-bb28-a0eabead1439 | |
Comparison | Eligibility | NCT02806544 | NCT00605267 | A patient with stage 2B , pathologically confirmed estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial. | Entailment | [
0,
5,
6
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02806544', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg by mouth daily', ' Tamoxifen: Tamoxifen 20mg by mouth daily'], 'Eligibility': ['Inclusion Criteria:', ' Patient evaluated and treated at INCAN', ' Patients must provide informed consent', ' Patient must be 18... | {'Clinical Trial ID': 'NCT00605267', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole (investigational product) 1mg tablet given once a day orally and goserelin acetate 3.6 mg/ month depot injection', 'INTERVENTION 2: ', ' Tamoxifen 20 mg', ' Tamoxifen (comparator) 20mg tablet given once a da... | c921d3a1-bd6e-41c9-b0e9-23babf7ead7c |
Comparison | Adverse Events | NCT02301988 | NCT00728949 | The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT02301988', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib + Paclitaxel', ' Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).', 'INTERVENTION 2: ', ' Placeb... | {'Clinical Trial ID': 'NCT00728949', 'Intervention': ['INTERVENTION 1: ', ' IMC-A12 (Cixutumumab) + Antiestrogen Therapy', ' Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory... | 358a1d3c-9ccc-48fc-badc-1644e326c8cb |
Comparison | Eligibility | NCT00045032 | NCT00416572 | WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident. | Contradiction | [
18
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00045032', 'Intervention': ['INTERVENTION 1: ', ' Observation Arm', ' Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the la... | {'Clinical Trial ID': 'NCT00416572', 'Intervention': ['INTERVENTION 1: ', ' Education Intervention', " Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enh... | 60a86c87-7387-4eae-b5dd-6245f8bf541e |
Single | Eligibility | NCT00090857 | Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded. | Contradiction | [
7,
8
] | [] | {'Clinical Trial ID': 'NCT00090857', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, duct... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bd3055c6-09aa-47f0-89ed-67ad3798a580 | |
Comparison | Eligibility | NCT00656019 | NCT00328783 | Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial. | Contradiction | [
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00656019', 'Intervention': ['INTERVENTION 1: ', ' Normal Vitamin D Levels', ' No additional Vitamin D administered', 'INTERVENTION 2: ', ' Low-normal Vitamin D Levels', ' 2000 IU dose of Vitamin D per day administered orally'], 'Eligibility': ['INCLUSION CRITERIA:', ' Undergoing core need... | {'Clinical Trial ID': 'NCT00328783', 'Intervention': ['INTERVENTION 1: ', ' Active Breathing Coordinator', ' Patients breathe through the ABC device', ' Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissu... | 21d7d726-8557-459f-a307-fae3e08f45d8 |
Single | Results | NCT00054132 | The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00054132', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Erlotinib Hydrochloride, Bevacizumab)', ' Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9a8157a9-82fc-4d7e-9254-295123459430 | |
Comparison | Adverse Events | NCT01856543 | NCT00365599 | Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01856543', 'Intervention': ['INTERVENTION 1: ', ' Eucerin', ' Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve applicati... | {'Clinical Trial ID': 'NCT00365599', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat and Tamoxifen', ' Vorinostat and Tamoxifen as outlined in Intervention Descriptions'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have cytologically/histologically documented locally advanced or metastatic breast cance... | ff37494d-2c61-4c06-86c1-d6bcfbe9e360 |
Comparison | Intervention | NCT01857882 | NCT01439945 | the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
7,
14,
15
] | {'Clinical Trial ID': 'NCT01857882', 'Intervention': ['INTERVENTION 1: ', ' Decision Support Workshop', ' The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates... | {'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', '... | eb00b609-f17b-4595-87bd-d0843ec9e39a |
Comparison | Intervention | NCT00904033 | NCT03592121 | Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial where the intervention must be applied during sexual activity. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00904033', 'Intervention': ['INTERVENTION 1: ', ' No Exercise', ' Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week', 'INTERVENTION 2: ', ' Exercise', ' Exercise Arm: Exercise consisting of progressive walking and resistance band training', ' Calcitriol+ Exercise Arm: ... | {'Clinical Trial ID': 'NCT03592121', 'Intervention': ['INTERVENTION 1: ', ' AB-101', ' Apply to both nipple/areola regions approximately 1 hour prior to sexual activity', ' AB-101: Apply approximately 1 hour prior to sexual activity', 'INTERVENTION 2: ', ' Placebo', ' Apply to both nipple/areola regions approximat... | 8bc9ea31-b731-4799-a1cc-a5ba63da00c1 |
Single | Results | NCT01684215 | In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01684215', 'Intervention': ['INTERVENTION 1: ', ' PD-0332991 100 mg: Dose Escalation Cohort', ' In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily co... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0864493d-9f64-49d1-a585-21be71704c59 | |
Single | Intervention | NCT02780713 | Both cohorts of the primary trial are administered the same doses of their respective drugs . | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c49428a7-cc55-474e-a773-88ff2019de1b | |
Comparison | Intervention | NCT00611624 | NCT00600340 | the primary trial and the secondary trial administer their interventions at different frequencies. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00611624', 'Intervention': ['INTERVENTION 1: ', ' Five Days of Mammosite Therapy', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' The patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines.', ' Patient m... | {'Clinical Trial ID': 'NCT00600340', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab Plus Paclitaxel', ' Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks', 'INTERVENTION 2: ', ' Bevacizumab Plus Capecitabine', ' Bevacizumab 15 mg/kg i.v.,... | 78136809-c8de-4c40-9a7e-1d61d879ba27 |
Single | Eligibility | NCT00009945 | Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00009945', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Clodronate', ' Patient receives 2 tablets once daily for 3 years.', ' clodronate: 1600 mg PO daily', 'INTERVENTION 2: ', ' Arm 2: Placebo', ' Patient receives 2 tablets once daily for 3 years.', ' placebo: 2 pills PO daily'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b430ea52-fa55-4280-9e23-8a7392afca58 | |
Single | Results | NCT00038103 | There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00038103', 'Intervention': ['INTERVENTION 1: ', ' Exemestane (Exemestane Alone)', ' oral dose exemestane taken with food (25 mg tablet once daily)', 'INTERVENTION 2: ', ' Combination (Exemestane + Celecoxib)', ' oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | adfeff22-7bdd-4868-ab6e-90dd43d9621d | |
Comparison | Adverse Events | NCT00371345 | NCT00475670 | There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00371345', 'Intervention': ['INTERVENTION 1: ', ' Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib', ' Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ h... | {'Clinical Trial ID': 'NCT00475670', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Monotherapy', ' Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once ever... | 51b8964b-86b8-4e93-9fb1-cb4b6f7f3451 |
Single | Adverse Events | NCT00468585 | the primary trial recorded several skin infections in their patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00468585', 'Intervention': ['INTERVENTION 1: ', ' Group 0', ' Capecitabine - AM 1500mg; PM 1500 mg; total daily 3000 mg', 'INTERVENTION 2: ', ' Group 1', ' Capecitabine - AM 1500 mg; PM 2000 mg; total daily 3500 mg'], 'Eligibility': ['Inclusion Criteria:', ' Patient (male or female) with ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 276f5523-f45b-45b0-ad30-b737f2c1b1d0 | |
Single | Eligibility | NCT00295867 | Patients with an ECOG score between 3-5 are eligible for the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00295867', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid', ' Patients who had greater than 4 disseminated tumor cells (DTCs)/mL present following neoadjuvant or adjuvant chemotherapy for early stage breast cancer were treated with 4mg zoledronic acid each month for 24 months.'], 'El... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 884ba067-d3fe-4837-ad2a-a802b671b53c | |
Single | Eligibility | NCT02222337 | Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT02222337', 'Intervention': ['INTERVENTION 1: ', ' Usual Care Survivors', ' Survivors randomized to usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family ther... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6619c75a-4073-47e9-8586-5070be1b3d39 | |
Comparison | Eligibility | NCT01816594 | NCT02222337 | Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50% | Contradiction | [
11
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01816594', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + BKM120 + Paclitaxel', ' BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.', 'INTERVENTION 2: ', ' Trastuzumab + BKM120 PBO + Paclitaxel', ' BKM120 placebo in combination with trastuzumab... | {'Clinical Trial ID': 'NCT02222337', 'Intervention': ['INTERVENTION 1: ', ' Usual Care Survivors', ' Survivors randomized to usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family ther... | d81fafa4-1196-407b-a8c2-27d7b5da2f4f |
Single | Adverse Events | NCT00320710 | There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients. | Contradiction | [
13,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00320710', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every (q) 4 Weeks', ' Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.', 'INTERVENTION 2: ', ' Zoledronic Acid q 12 Weeks', ' Participants received 4 mg zoledronic acid IV q 12 weeks and re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6d8b4720-e600-47d7-b6c5-3b8627f2358f | |
Comparison | Intervention | NCT01646346 | NCT03283553 | the secondary trial and the primary trial do not use topical medications in their studies. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01646346', 'Intervention': ['INTERVENTION 1: ', ' 4D Conformal Image-Guided Partial Breast RT', ' This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.', ' 4D Conformal Image-Guided Partial Breast RT: External bea... | {'Clinical Trial ID': 'NCT03283553', 'Intervention': ['INTERVENTION 1: ', ' Multicomponent Intervention', " 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss ... | 1b84007d-0002-4ab6-8e05-609e7de58684 |
Comparison | Eligibility | NCT00213980 | NCT02536339 | Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | {'Clinical Trial ID': 'NCT00213980', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid (ZA)', ' ZA', ' Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles', 'INTERVENTION 2: ', ' Observation', ' Observation only for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': 'NCT02536339', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab', ' Participants with CNS metastases secondary to HER2-positive MBC, who had disease progression in the brain following previous treatment with radiotherapy (whole-brain radiation therapy or stereotactic radiosurgery)... | dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009 |
Single | Adverse Events | NCT01007942 | Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2. | Entailment | [
0,
4,
12,
16
] | [] | {'Clinical Trial ID': 'NCT01007942', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Vinorelbine + Trastuzumab', ' Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', 'INTERVENTION 2: ', ' Pl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dc7c4409-32e5-4211-83fe-0a97b6176ca0 | |
Single | Results | NCT00337103 | Several patients in the Eribulin Mesylate group in the primary trial survived less than a year. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00337103', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.', 'INTERVENTION 2: ', ' Capecitabine 2.5 g/m^2/Day', ' Capecitabine : Capecitabine 2.5 g/m^2/day a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 73e7447b-a940-4126-a1d9-fffd7c56c900 | |
Single | Eligibility | NCT00629499 | Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial. | Contradiction | [
0,
13
] | [] | {'Clinical Trial ID': 'NCT00629499', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' 100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment per... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c160ae6e-4dfe-47a4-ac9a-7497babbc2a2 | |
Comparison | Eligibility | NCT00129389 | NCT00304096 | Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial. | Contradiction | [
22,
30
] | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53
] | {'Clinical Trial ID': 'NCT00129389', 'Intervention': ['INTERVENTION 1: ', ' Arm A: FAC', ' FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.', 'INTERVENTION 2: ', ' Arm B: FAC-wP', ' FAC X 4 + 8 weekl... | {'Clinical Trial ID': 'NCT00304096', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Received Hormonal Therapy', ' Participants received hormonal therapy', 'INTERVENTION 2: ', ' Stratum 2: Had Not Received Hormonal Therapy', ' Participants had not received hormonal therapy'], 'Eligibility': ['DISEASE CHARACTERIST... | 9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063 |
Single | Eligibility | NCT01908101 | Prior exposure to taxane is obligatory for patients in the primary trial. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01908101', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Eribulin Mesylate)', ' Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' Eribulin Mesylate: Given IV', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a7106a35-36da-423a-a6b3-3da62fc0eea8 | |
Comparison | Intervention | NCT00952731 | NCT00956813 | Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO. | Contradiction | [
5,
6,
7,
8,
9
] | [
3,
4,
5
] | {'Clinical Trial ID': 'NCT00952731', 'Intervention': ['INTERVENTION 1: ', ' Treatment Gel + Oral Placebo', ' 4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.', ' oral placebo: Oral placebo taken daily for 4-10 weeks.', ' afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 w... | {'Clinical Trial ID': 'NCT00956813', 'Intervention': ['INTERVENTION 1: ', ' Flaxseed', ' Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', 'INTERVENTION 2: ', ' Placebo', ' Patients Identical looking bar with same calorie and total fat content but without flaxsee... | f4f50a05-9d63-4006-9680-b7ef68dbb5fe |
Single | Eligibility | NCT00741260 | Patients with HER2 positive tumors are ineligible for the primary trial. | Contradiction | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT00741260', 'Intervention': ['INTERVENTION 1: ', ' N160 + C1500', ' Neratinib 160 mg + Capecitabine 1500 mg/m2', 'INTERVENTION 2: ', ' N160 + C2000', ' Neratinib 160 mg + Capecitabine 2000 mg/m2'], 'Eligibility': ['INCLUSION CRITERIA', ' PART 1:', ' confirmed pathologic diagnosis of a sol... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f34760f4-965e-4bbb-b88f-8b63a7045808 | |
Single | Adverse Events | NCT00866905 | Less than 2% of patients in the primary trial experienced an adverse event. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00866905', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Cyclophosphamide', ' Systemic Therapy followed by surgery and possible radiation therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years.', ' Histologically confirmed invasive adenocarcinoma of the brea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f4a33395-7e6b-46b9-b222-af3bbfff1591 | |
Single | Adverse Events | NCT01421472 | More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT01421472', 'Intervention': ['INTERVENTION 1: ', ' HR+: MM-121+ Paclitaxel', ' Hormone-receptor positive (HR+) sub-group randomized to receive:', ' 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose), followed by 4 cycles of MM-121 (20 mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7d00591-381f-45e2-abdb-2ae1e568b193 | |
Comparison | Adverse Events | NCT00885755 | NCT01075100 | Patients' appetites were not affected in the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT00885755', 'Intervention': ['INTERVENTION 1: ', ' Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks)', ' This group included participants who progressed after at least six weeks of trastuzumab/taxane treatment. In Part 1 of the study, participants received standard first-line therapy with t... | {'Clinical Trial ID': 'NCT01075100', 'Intervention': ['INTERVENTION 1: ', ' Triple Negative', ' ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.', 'INTERVENTION 2: ', ' HR Positive', ' ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/H... | 59da1fb5-2636-4ca8-8970-6cb45dedbed3 |
Comparison | Intervention | NCT04030104 | NCT02525718 | Intervention 1 for the secondary trial and the primary trial are for the control groups. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT04030104', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' One analyzable mass per patient: BI-RADS 3 and 4a, 4b, 4c and 5 masses as declared by clinical site investig... | {'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will rece... | f144c34b-9428-4836-bf01-5f7030eb579c |
Comparison | Eligibility | NCT02073487 | NCT03371732 | Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02073487', 'Intervention': ['INTERVENTION 1: ', ' T-DM1 + Lapatinib + Abraxane', ' T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.', ' T-DM1: antibody-drug conjugate of trastuzumab and emtansine', ' Lapatinib: Dua... | {'Clinical Trial ID': 'NCT03371732', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single ... | e7e87023-2227-4594-931a-0a3d89ec686e |
Single | Adverse Events | NCT02149524 | Several adverse events which occurred in the primary trial were not heart related. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02149524', 'Intervention': ['INTERVENTION 1: ', ' Herceptin (Trastuzumab)', ' Intravenous administration', ' Herceptin (trastuzuamb): Intravenous administration', 'INTERVENTION 2: ', ' SB3 (Proposed Trastuzumab Biosimilar)', ' Intravenous administration', ' SB3 (proposed trastuzumab bios... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ca4a190a-9007-4f8f-a199-b8fe4064e55b | |
Comparison | Intervention | NCT00711529 | NCT02835625 | the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00711529', 'Intervention': ['INTERVENTION 1: ', ' Hypnotherapy', ' Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of sel... | {'Clinical Trial ID': 'NCT02835625', 'Intervention': ['INTERVENTION 1: ', ' Digital Breast Tomosynthesis', ' Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for furth... | 4f790768-7fa4-4729-bcd6-cf7bcb44fa3c |
Comparison | Intervention | NCT02685566 | NCT03076190 | the primary trial and the secondary trial have the same number of study groups, but are testing different interventions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02685566', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.', ' This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in can... | {'Clinical Trial ID': 'NCT03076190', 'Intervention': ['INTERVENTION 1: ', ' Active Control Group', ' Health Education Active Control Group', 'INTERVENTION 2: ', ' My Surgical Success Treatment Group', ' My Surgical Success Intervention Group'], 'Eligibility': ['Inclusion Criteria:', ' Age 18+', ' Scheduled for br... | cb133915-dc40-4f93-a6a7-076e4d7f07a1 |
Comparison | Eligibility | NCT00045032 | NCT00416572 | WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial. | Entailment | [
18
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00045032', 'Intervention': ['INTERVENTION 1: ', ' Observation Arm', ' Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the la... | {'Clinical Trial ID': 'NCT00416572', 'Intervention': ['INTERVENTION 1: ', ' Education Intervention', " Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enh... | 1f0825b6-8e32-44ff-96b7-ab082e24b493 |
Comparison | Eligibility | NCT00375427 | NCT00579826 | Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [
6,
7
] | {'Clinical Trial ID': 'NCT00375427', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every 3 Months', ' Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 ... | {'Clinical Trial ID': 'NCT00579826', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, daily for 6 months', ' Placebo: Placebo... | db96c4d6-ffcd-401a-8af3-807f665f16f7 |
Single | Eligibility | NCT00976989 | Patients with LVEF equal to 53.5% are eligible for the primary trial. | Contradiction | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT00976989', 'Intervention': ['INTERVENTION 1: ', ' T+P Concomitant Anthracycline-based Chemotherapy', ' 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b74dc1bc-76c3-4ce6-9735-634e7a507ff5 | |
Comparison | Eligibility | NCT01740323 | NCT00127205 | the secondary trial and the primary trial only accept 18 year olds. | Contradiction | [
0,
1
] | [
15,
16,
17
] | {'Clinical Trial ID': 'NCT01740323', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo', ' Placebo: daily placebo for 6 weeks', 'INTERVENTION 2: ', ' Curcumin', ' 500 mg BID', ' Curcumin: 500 mg BID'], 'Eligibility': ['Inclusion Criteria:', ' Female breast cancer patients over the age of 18 will be recr... | {'Clinical Trial ID': 'NCT00127205', 'Intervention': ['INTERVENTION 1: ', ' Arm I Zoledronate', ' Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.', ' zoledronic acid: Given IV', 'INTERVENTION 2: ', ' Arm II Clodronate', ' Patients receive oral c... | f078c722-b879-40f2-ac72-c733001b93dd |
Comparison | Results | NCT02041429 | NCT00068588 | the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02041429', 'Intervention': ['INTERVENTION 1: ', ' All Phase I Participants', ' Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib orally twice daily according to the established dose escalation schedule for 4 cycles', ' 1 cycle = 21 days Participants with stable disease or better will have the opp... | {'Clinical Trial ID': 'NCT00068588', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle,', 'INTERVENTION 2: ', ' Arm 2', ' Capecitabine 1000 mg/m... | c33d78e5-13be-4cde-b36e-7cc097f180a2 |
Comparison | Intervention | NCT00075270 | NCT01781299 | the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00075270', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib With Paclitaxel', ' Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was strati... | {'Clinical Trial ID': 'NCT01781299', 'Intervention': ['INTERVENTION 1: ', ' AlloDerm RTU', ' Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.', 'AlloDerm RTU', 'INTERVENTION 2: ', ' SurgiMend PRS', ' Participants within this arm will... | 58dbc33b-d32c-4e91-a940-ca1148bbdae4 |
Comparison | Intervention | NCT00602043 | NCT01720602 | Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00602043', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FES: Average FES SUVmean >1.5, no Negative Sites', ' Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.', ' P... | {'Clinical Trial ID': 'NCT01720602', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vorinostat, AI Therapy)', ' Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat e... | fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e |
Single | Adverse Events | NCT01216176 | Urosepsis was the only recorded adverse event in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT01216176', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 - Cohort A', ' Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer', ' Anastrozole',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2c462296-35f5-482a-9ece-3b4ed4c2f53a | |
Single | Eligibility | NCT01196052 | Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy. | Contradiction | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01196052', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Adult patients 18 years of age.', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 16358be6-3895-48f7-8006-4effeb3f74b3 | |
Comparison | Eligibility | NCT00703326 | NCT00274768 | Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial. | Contradiction | [
0,
3,
5
] | [
0,
1,
7,
8
] | {'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 mil... | {'Clinical Trial ID': 'NCT00274768', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until u... | 6d4ecb16-6586-4ea8-a1dc-f825e951e060 |
Comparison | Adverse Events | NCT01252290 | NCT00479674 | Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01252290', 'Intervention': ['INTERVENTION 1: ', ' Lovaza™', ' Lovaza™: 4 capsules daily for 6 months'], 'Eligibility': ['Inclusion Criteria', ' Subjects must be postmenopausal and between the ages of 25 and 69 years. Menopause is defined by no menstrual period for more than one year and int... | {'Clinical Trial ID': 'NCT00479674', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Carboplatin, Bevacizumab', ' Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15', ' Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every... | 5bb009f0-bc19-4a85-85b8-bd7bf0675f3f |
Comparison | Results | NCT01323530 | NCT01106040 | the secondary trial and the primary trial do not have comparable Outcome Measurements. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day ... | {'Clinical Trial ID': 'NCT01106040', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | 2731552d-195a-4f43-b6b5-02a3fbda81d9 |
Single | Results | NCT01231659 | Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01231659', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Letrozole', ' All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.'], 'Eligibility': ['Inclusion Criteria:'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8fee5ce4-3e46-4731-842e-a5b1df451c7d | |
Single | Intervention | NCT02518191 | Cohort 2 of the primary trial is the control group. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT02518191', 'Intervention': ['INTERVENTION 1: ', ' GnRHa (Gonadotrophin-releasing Hormone Analogues) Group', ' Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.', ' Goserelin 3.6mg, or leuprorelin 3.75mg subcutan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | def4199f-a22d-4939-b15d-66fd073fb280 | |
Single | Adverse Events | NCT00871858 | 1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00871858', 'Intervention': ['INTERVENTION 1: ', ' Arm A (ANA)', ' Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.', ' anastrozole: Given orally', 'INTERVENTION 2: ', ' Arm B (FULV)', ' Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solut... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2 | |
Comparison | Eligibility | NCT03624972 | NCT01216176 | A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial. | Contradiction | [
4,
7
] | [
56,
73
] | {'Clinical Trial ID': 'NCT03624972', 'Intervention': ['INTERVENTION 1: ', ' Resources Only', ' Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.', ' Sexual and Menopausal Health Resources: Patients wi... | {'Clinical Trial ID': 'NCT01216176', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 - Cohort A', ' Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer', ' Anastrozole',... | d97c3981-50f9-4221-aec6-60661b831c8e |
Single | Eligibility | NCT01028352 | Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial. | Contradiction | [
0,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01028352', 'Intervention': ['INTERVENTION 1: ', ' Duloxetine', ' Participants took 30 mg oral capsules once a day for 7 days, then 60 mg per mouth once per day for 21 days. After 4 weeks if pain had decreased, subjects continued 60 mg. per mouth once per day for 4 weeks. If pain had not decr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 86c1430c-553b-4388-a034-b82f78afdc0d | |
Single | Intervention | NCT01905592 | both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01905592', 'Intervention': ['INTERVENTION 1: ', " Physician's Choice", ' Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine), until progression or unacceptable toxicity develops.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b7cef0e1-7bd8-4c0e-a044-b11708cf927c | |
Single | Adverse Events | NCT00444587 | A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea. | Contradiction | [
3,
6,
8
] | [] | {'Clinical Trial ID': 'NCT00444587', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + 2nd Line Chemotherapy', ' Eligible participants were administered trastuzumab 6 mg/kg of body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion, every three weeks until disease progression, unaccepta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0b55d5b7-5e71-497f-96ad-9dc2f872c4aa | |
Comparison | Eligibility | NCT01217385 | NCT01202591 | Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
6,
7
] | {'Clinical Trial ID': 'NCT01217385', 'Intervention': ['INTERVENTION 1: ', ' Diffuse Optical Spectroscopy Imaging (DOSI', ' Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.', ' DOSI: Bedside DOSI images of the tissu... | {'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menop... | 225f95a5-7c22-4cb7-a463-1c57d5b69d7a |
Comparison | Intervention | NCT03061175 | NCT03098550 | Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03061175', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Web-Based CPM-DA)', ' Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary... | {'Clinical Trial ID': 'NCT03098550', 'Intervention': ['INTERVENTION 1: ', ' Nivolumab + Daratumumab (TNBC)', ' Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/... | 5464e8a7-159c-4e00-8710-45a44ceaeda3 |
Comparison | Adverse Events | NCT00382018 | NCT03012477 | Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
5
] | {'Clinical Trial ID': 'NCT00382018', 'Intervention': ['INTERVENTION 1: ', ' Arm C1 (Baseline CTCs >= 5, Day 22 CTCs >= 5, High Risk)', ' Patients had increased CTCs at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTCs at first follow-up (Day 22). Patients would be randomized to maintain current ther... | {'Clinical Trial ID': 'NCT03012477', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin + AZD1775', ' Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 m... | 98965d07-e2db-41bf-ac3e-a5c130513275 |
Comparison | Eligibility | NCT00429104 | NCT00878709 | Patients with end-stage liver disease are excluded from the primary trial and the secondary trial. | Contradiction | [
7,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00429104', 'Intervention': ['INTERVENTION 1: ', ' HER2+ Metastatic Breast Cancer', ' Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously'], 'Eligibility': ['Inclusion Criteria:', ' Histological confirmatio... | {'Clinical Trial ID': 'NCT00878709', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxici... | 784cc905-937f-43fd-96a6-34ea8dce9e8d |
Comparison | Results | NCT00706030 | NCT00171704 | the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00706030', 'Intervention': ['INTERVENTION 1: ', ' Neratinb 240 mg + Vinorelbine 25 mg/m² - No Prior Lapatinib', ' Neratinib 240 mg qd + Vinorelbine 25 mg/m² IV on days 1 and 8 every 3 weeks, with no prior lapatinib exposure', 'INTERVENTION 2: ', ' Neratinib 240 mg + Vinorelbine 25 mg/m² - P... | {'Clinical Trial ID': 'NCT00171704', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg once daily (q.d.)orally for 5 years', 'INTERVENTION 2: ', ' Tam-Let', ' 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.'], 'Eligibility': ['Inclusion Criteria',... | 2e3f2fde-569e-46ef-958d-710599fec9a1 |
Single | Intervention | NCT00106002 | the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00106002', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed', ' 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression'], 'Eligibility': ['Inclusion Criteria:', ' Must have been diagnosed with either advanced or metastatic breast cancer.', ' Chemotherapy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d1080199-2591-44bd-bdad-0dea3830e657 | |
Comparison | Intervention | NCT02352779 | NCT00263588 | The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02352779', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Low-dose Omega-3 Fatty Acid)', ' Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Placebo: Given PO', ' Questionnaire Administration: Ancillary st... | {'Clinical Trial ID': 'NCT00263588', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast canc... | c37c21f5-19a0-4fcc-af92-89690fb64091 |
Comparison | Adverse Events | NCT01276041 | NCT00688909 | 0 patients in the primary trial or the secondary trial died. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclus... | {'Clinical Trial ID': 'NCT00688909', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with HR+ early stage breast cancer at the time of i... | bea7f10e-09d6-42c3-9e89-dfd1112a33d5 |
Single | Intervention | NCT00545077 | Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00545077', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Endocrine Therapy (ET)', ' Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. T... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3d41d86b-f53f-4bf9-a4dd-eae2412c485e | |
Comparison | Adverse Events | NCT01015131 | NCT00312208 | Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01015131', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants who underwent 18-FLT positron emission tomography (PET) and standard of care (SOC) neo-adjuvant chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Has newly-diagnosed stage IIB/IIIA/IIIB locally advanc... | {'Clinical Trial ID': 'NCT00312208', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks f... | 0159bfb3-231e-4711-b3ee-2798c66f5f6a |
Comparison | Adverse Events | NCT00392392 | NCT00503906 | the primary trial records two different types of pain in its adverse events, in the cranial and foot area, the secondary trial does not record any types of pain in its participants. | Contradiction | [
0,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00392392', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and b... | {'Clinical Trial ID': 'NCT00503906', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Avastin and Gemcitabine', ' Each treatment cycle is 28 days. Participants will be treated until disease progression:', ' Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 a... | 9e7628cd-931e-4b1f-b4c1-f03f0449ac27 |
Single | Adverse Events | NCT00312208 | Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00312208', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f1108cbc-db27-431d-9154-1a267278bda4 | |
Single | Eligibility | NCT04396665 | Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet. | Entailment | [
0,
1,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT04396665', 'Intervention': ['INTERVENTION 1: ', ' Intervention Group', ' Women in the intervention group', 'INTERVENTION 2: ', ' Control Group', ' Women in the control group'], 'Eligibility': ['Inclusion Criteria:', ' Informed consent signed', ' Capability to use internet', 'Exclusion Cr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8eb69e3e-ac08-4e85-98be-211aecd4525d | |
Single | Results | NCT01432886 | None of the patients in either cohort of the primary trial experienced DLT. | Entailment | [
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01432886', 'Intervention': ['INTERVENTION 1: ', ' E7389 With Weekly Trastuzumab', ' Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | baf7e338-91fd-47d0-b766-a4e039efc5d7 | |
Single | Eligibility | NCT00458237 | Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial. | Contradiction | [
0,
6,
12,
21
] | [] | {'Clinical Trial ID': 'NCT00458237', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9401b12d-3888-4a41-93a1-b2075930098b | |
Comparison | Eligibility | NCT00908791 | NCT00297596 | Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial. | Entailment | [
0,
10
] | [
0,
21
] | {'Clinical Trial ID': 'NCT00908791', 'Intervention': ['INTERVENTION 1: ', ' Pre CLA', ' Women with histologically proven invasive non-metastatic breast cancer.', 'INTERVENTION 2: ', ' Post CLA', ' Women with histologically proven invasive non-metastatic breast cancer.'], 'Eligibility': ['Inclusion Criteria:', ' Al... | {'Clinical Trial ID': 'NCT00297596', 'Intervention': ['INTERVENTION 1: ', ' Oxaliplatin/Trastuzumab', ' Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxalipla... | c7aa030a-6b76-4bd7-a934-f02a4638a1ac |
Single | Results | NCT01823107 | several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94f9a957-33bb-4409-8878-ba734d6b0d5c | |
Comparison | Adverse Events | NCT00087152 | NCT00203502 | the primary trial recorded less patients with nausea than the secondary trial. | Entailment | [
0,
3
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00087152', 'Intervention': ['INTERVENTION 1: ', ' Imatinib Mesylate & Capecitabine', ' Imatinib Mesylate 400 mg by mouth daily for 21 day cycle. Capecitabine 1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle.'], 'Eligibility': ['Histologically or cytologically confirmed adenoc... | {'Clinical Trial ID': 'NCT00203502', 'Intervention': ['INTERVENTION 1: ', ' Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter... | 04fd88c2-cf92-468d-bbc4-567cae19948d |
Comparison | Adverse Events | NCT00499122 | NCT00454805 | There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00499122', 'Intervention': ['INTERVENTION 1: ', ' NOV-002 and Chemotherapy', ' NOV-002:', ' Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart', ' Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration', ' Cycle 1 - 8, D... | {'Clinical Trial ID': 'NCT00454805', 'Intervention': ['INTERVENTION 1: ', ' Cediranib 45 mg', ' Cediranib 45 mg+Fulvestrant 250 mg', ' Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:', ' Day 1: fulvestrant 500 mg im', ' Day 15: fulves... | 8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd |
Comparison | Eligibility | NCT00375427 | NCT00579826 | Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [
6,
7
] | {'Clinical Trial ID': 'NCT00375427', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every 3 Months', ' Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 ... | {'Clinical Trial ID': 'NCT00579826', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, daily for 6 months', ' Placebo: Placebo... | 8074c35f-b74c-4250-94f1-9ad22fa315d7 |
Comparison | Eligibility | NCT00580333 | NCT00934856 | Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial. | Contradiction | [
8,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT00580333', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin/Avastin', ' Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preopera... | {'Clinical Trial ID': 'NCT00934856', 'Intervention': ['INTERVENTION 1: ', ' MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)', ' Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/... | afc4a45b-6592-4ca8-b174-033fb6a0624a |
Single | Eligibility | NCT00033514 | Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00033514', 'Intervention': ['INTERVENTION 1: ', ' Treatment Phase 1 Plus Phase 2', ' trastuzumab: Day 1 4mg/kg IV 2 mg/kg IV weekly.', ' erlotinib hydrochloride: 150 mg daily.'], 'Eligibility': ['Inclusion Criteria:', ' Women aged > 18 years', ' Histologically documents metastatic breast ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e1d4811-ae58-4b81-b53a-dbcb8c980a08 | |
Comparison | Eligibility | NCT00568022 | NCT01120184 | Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00568022', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day', ' Ixabepilone 32 mg/m^2 was administered via intravenous (IV) infusion over 3 hours on Day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on Days 1 to 14 ... | {'Clinical Trial ID': 'NCT01120184', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Taxane', " Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day... | d4f738c5-c99a-4d8d-b335-5821ce97fbd5 |
Single | Adverse Events | NCT01262027 | More than 1 patient in the primary trial suffered an adverse event. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01262027', 'Intervention': ['INTERVENTION 1: ', ' Dovitinib', ' Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Patients have histological confirmati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f27b25bd-c28e-4aac-8ad6-951fd7381ce4 | |
Comparison | Adverse Events | NCT00127933 | NCT00191789 | the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed. | Contradiction | [
12,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00127933', 'Intervention': ['INTERVENTION 1: ', ' HER2-Neu Negative', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week t... | {'Clinical Trial ID': 'NCT00191789', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, eve... | 5311216c-94e0-4d04-acd2-b95b932ddc02 |
Single | Adverse Events | NCT00191451 | Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00191451', 'Intervention': ['INTERVENTION 1: ', ' HER2+', ' Human Epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptin.', ' Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplati... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 01dfa37b-ce65-4e90-addc-395241c92f5f | |
Single | Eligibility | NCT03197389 | Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial. | Entailment | [
0,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT03197389', 'Intervention': ['INTERVENTION 1: ', ' Cohort A1', ' Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab:... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43588c50-7dc4-4d46-a53d-e94576e8ab55 | |
Single | Eligibility | NCT02683083 | sufferers of hyperthyroidism are excluded from the primary trial. | Entailment | [
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT02683083', 'Intervention': ['INTERVENTION 1: ', ' [131I]-SGMIB Anti-HER2 VHH1', ' All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).'], 'Eligibility': ['Inclusion Criteria:', ' Subjects will only be included in the st... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f419f810-ca53-4168-86fd-d1d9a9154d3a | |
Single | Results | NCT00206518 | The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22
] | [] | {'Clinical Trial ID': 'NCT00206518', 'Intervention': ['INTERVENTION 1: ', ' A: Taxotere/Docetaxel', ' Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 630a8241-b776-4799-a7ca-b1fddf17686c | |
Comparison | Eligibility | NCT00675259 | NCT01875367 | Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial. | Entailment | [
15,
18
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00675259', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant, Surgery, Adjuvant', " Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel... | {'Clinical Trial ID': 'NCT01875367', 'Intervention': ['INTERVENTION 1: ', ' Arm A: T-IV + T-SC Vial + T-SC Device', ' Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with si... | 8f3fddf2-97ab-4456-bff7-8f83b27e3849 |
Comparison | Intervention | NCT00485953 | NCT00068601 | the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00485953', 'Intervention': ['INTERVENTION 1: ', ' Active Medicine Group', ' risedronate 35 mg weekly', 'INTERVENTION 2: ', ' Placebo Group', ' Received placebo medication once weekly'], 'Eligibility': ['Inclusion Criteria:', ' elderly postmenopausal women (ages 55 and older)', ' osteopen... | {'Clinical Trial ID': 'NCT00068601', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patients receive cyclophosphamide-containing chemotherapy alone.', ' cyclophosphamide: Part of planned chemotherapy regimen', 'INTERVENTION 2: ', ' Chemotherapy Plus Goserelin', ' Patients receive goserelin subcut... | 11617367-193f-4f6b-bc3e-e58ea76d1052 |
Comparison | Eligibility | NCT01840163 | NCT02005549 | the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT01840163', 'Intervention': ['INTERVENTION 1: ', ' CanSORT Online Tool (Intervention)', ' Comprehensive (interactive) version of decision tool', ' CanSORT Online Tool', 'INTERVENTION 2: ', ' Static Version of CanSORT Tool (Control)', ' Static version (non-interactive) version of CanSORT de... | {'Clinical Trial ID': 'NCT02005549', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab+Docetaxel+Capecitabine', ' Participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on Day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes after the end of a meal, starting the evening of Day 1 and... | 882f22f6-36d9-4c2f-8f49-52469d570977 |
Single | Adverse Events | NCT01250379 | None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation. | Contradiction | [
0,
8,
5,
7,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01250379', 'Intervention': ['INTERVENTION 1: ', ' CT Arm', " Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator's site until disease progression, unacceptable toxicity, participant request for withdraw... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8f5423c9-17b5-4f66-aa9f-1fc9763958b2 | |
Single | Adverse Events | NCT00846027 | None of the adverse events recorded for the primary trial occurred less than twice. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptabl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0c45a782-1a3d-4e9b-a258-136ab080dbb6 | |
Single | Eligibility | NCT00654836 | Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial. | Contradiction | [
0,
1,
2,
3,
5
] | [] | {'Clinical Trial ID': 'NCT00654836', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, ABI-007 and Bevacizumab', " Participants received combination carboplatin, ABI-007 (i.e., a nanoparticle albumin-bound paclitaxel also called Abraxane), and bevacizumab (Avastin). Bevacizumab was administered as 15 mg/kg on days ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4e42302d-2cd9-4a91-9338-8e3b0ffb9292 | |
Single | Results | NCT00270894 | 60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00270894', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Therapy', ' Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuz... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a5d5e6da-f3cd-49c7-92a7-f789468c4c4c | |
Single | Eligibility | NCT00981812 | Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial. | Entailment | [
5,
8
] | [] | {'Clinical Trial ID': 'NCT00981812', 'Intervention': ['INTERVENTION 1: ', ' Lesions Visualized Using Positron Emission Mammography (PEM)', ' Total lesions visualized using positron emission mammography.'], 'Eligibility': ['Inclusion Criteria:', ' female', ' subject is 25-100 years of age', ' subjects has at least ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | da2ea2e9-3109-433e-9033-9ae322c30c4b | |
Single | Adverse Events | NCT00863655 | There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2. | Entailment | [
0,
1,
2,
3,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00863655', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Exemestane', ' Everolimus 10 mg daily in combination with exemestane 25 mg daily', 'INTERVENTION 2: ', ' Placebo + Exemestane', ' Placebo of everolimus in combination with exemestane 25 mg daily'], 'Eligibility': ['Inclusion Cr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c77c8e02-7abb-4b63-8917-01babe5cd372 | |
Single | Intervention | NCT00911898 | the primary trial does not explain its intervention in the intervention section. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00911898', 'Intervention': ['INTERVENTION 1: ', ' MM-111', 'All participants'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed advanced cancer that is:', ' HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation', ' Hereg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f2b14720-6ff2-4ff7-a5bc-3841b93f647e | |
Comparison | Eligibility | NCT00568022 | NCT01120184 | Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00568022', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/Day', ' Ixabepilone 32 mg/m^2 was administered via intravenous (IV) infusion over 3 hours on Day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on Days 1 to 14 ... | {'Clinical Trial ID': 'NCT01120184', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Taxane', " Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day... | 03e9368b-18a7-4643-a38b-a7b002403bf1 |
Single | Results | NCT00422903 | Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00422903', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + Placebo', ' Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.', 'INTERVENTION 2: ', ' Letrozole + Lapatinib', ' Letrozole tablets in the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c5dbd52d-01d4-4919-bfe9-2b7885490d6a | |
Comparison | Eligibility | NCT00630032 | NCT00428922 | Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial. | Contradiction | [
13,
14
] | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00630032', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel', ' 3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)', ' Cyclophosphamide: 500 mg/m² every 3 weeks Docetaxel: 100 mg/m² every 3 weeks Epirubicin hydroch... | {'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER... | 83115abd-1c07-4ee7-8ba5-b4575be2d50f |
Comparison | Intervention | NCT01857882 | NCT01439945 | the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
7,
14,
15
] | {'Clinical Trial ID': 'NCT01857882', 'Intervention': ['INTERVENTION 1: ', ' Decision Support Workshop', ' The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates... | {'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', '... | 784872db-8ccf-4ddc-a432-6ee00fd0b0cc |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.